{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T04:48:44Z","timestamp":1766810924301,"version":"3.48.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eplepsyres.2025.107696","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T07:41:16Z","timestamp":1763538076000},"page":"107696","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The effectiveness and safety of lacosamide in infants with epilepsy aged under 2 years: A prospective study"],"prefix":"10.1016","volume":"219","author":[{"given":"Liu","family":"Tailin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiong","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Jing","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wang","family":"Jiayi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Nong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2025.107696_bib1","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-3908","article-title":"Incidence and prevalence of childhood epilepsy: a nationwide cohort study","volume":"139","author":"Aaberg","year":"2017","journal-title":"Pediatrics"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib2","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejpn.2015.12.013","article-title":"Clinical experience of intravenous lacosamide in infants and young children","volume":"20","author":"Arkilo","year":"2016","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib3","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1111\/j.1528-1167.2007.01188.x","article-title":"Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures","volume":"48","author":"Ben-Menachem","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib4","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1528-1167.2012.03725.x","article-title":"Tolerability, pharmacokinetics, and bioequivalence of the tablet and syrup formulations of lacosamide in plasma, saliva, and urine: saliva as a surrogate of pharmacokinetics in the central compartment","volume":"54","author":"Cawello","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib5","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1528-1167.2009.02496.x","article-title":"Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial","volume":"51","author":"Chung","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib6","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib7","article-title":"Effectiveness and tolerability of lacosamide in children with drug resistant epilepsy","volume":"21","author":"Driessen","year":"2023","journal-title":"Epilepsy Behav. Rep."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib8","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1111\/epi.12046","article-title":"A population-based study of newly diagnosed epilepsy in infants","volume":"54","author":"Eltze","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib9","unstructured":"EMA, 2024. An overview of vimpat and why it is authorised in the EU. \u3008https:\/\/www.ema.europa.eu\/en\/documents\/overview\/vimpat-epar-medicine-overview_en.pdf\u3009 (accessed 2024-10-3)."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib10","doi-asserted-by":"crossref","first-page":"e1212","DOI":"10.1212\/WNL.0000000000008126","article-title":"Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures","volume":"93","author":"Farkas","year":"2019","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib11","unstructured":"FDA, 2024. Vimpat prescribing information. \u3008https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/022253s049,022254s039,022255s031lbl.pdf\u3009 (accessed 2024-10-3)."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib12","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.seizure.2019.05.016","article-title":"Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures \u2013 an open-label trial","volume":"71","author":"Ferreira","year":"2019","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib13","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1111\/epi.17676","article-title":"Safety of intravenous lacosamide in hospitalized children and neonates","volume":"64","author":"Fong","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.eplepsyres.2015.02.008","article-title":"Lacosamide use in the treatment of refractory epilepsy in tuberous sclerosis complex","volume":"112","author":"Geffrey","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib15","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1016\/j.eplepsyres.2014.08.021","article-title":"Lacosamide efficacy in epileptic syndromes with continuous spike and waves during slow sleep (CSWS)","volume":"108","author":"Grosso","year":"2014","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib16","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ane.12221","article-title":"Efficacy and tolerability of add-on lacosamide in children with lennox-gastaut syndrome","volume":"129","author":"Grosso","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib17","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1528-1167.2008.01951.x","article-title":"Adjunctive lacosamide for partial-onset seizures: efficacy and safety results from a randomized controlled trial","volume":"50","author":"Halasz","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib18","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/epi.13602","article-title":"Activity of the anticonvulsant lacosamide in experimental and human epilepsy via selective effects on slow na(+) channel inactivation","volume":"58","author":"Holtkamp","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib19","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.eplepsyres.2015.02.003","article-title":"Retention rates of rufinamide in pediatric epilepsy patients with and without lennox-gastaut syndrome","volume":"112","author":"Kessler","year":"2015","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107580","article-title":"The effects of lacosamide on cognitive function and psychiatric profiles in patients with epilepsy","volume":"113","author":"Li","year":"2020","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2020.107654","article-title":"Developmental and epileptic encephalopathies: is prognosis related to different epileptic network dysfunctions?","volume":"131","author":"Lin","year":"2022","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib22","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1007\/s40262-017-0530-8","article-title":"Time-to-seizure modeling of lacosamide used in monotherapy in patients with newly diagnosed epilepsy","volume":"56","author":"Lindauer","year":"2017","journal-title":"Clin. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib23","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1002\/acn3.52004","article-title":"Efficacy and tolerability of adjunctive lacosamide in patients aged <4 years with focal seizures","volume":"11","author":"Makedonska","year":"2024","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib24","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1111\/epi.17601","article-title":"Long-term effectiveness of add-on perampanel in patients with lennox-gastaut syndrome: a multicenter retrospective study","volume":"64","author":"Matricardi","year":"2023","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib25","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1111\/epi.13466","article-title":"Lacosamide use in children with epilepsy: retention rate and effect of concomitant sodium channel blockers in a large cohort","volume":"57","author":"McGinnis","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib26","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.seizure.2018.04.015","article-title":"Evaluating the longer-term cognitive effects of adjunctive perampanel compared to lacosamide in a naturalistic outpatient setting","volume":"58","author":"Meschede","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib27","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/0883073816630084","article-title":"Efficacy and tolerability of lacosamide in the treatment of children with refractory generalized epilepsy","volume":"31","author":"Miskin","year":"2016","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib28","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.pediatrneurol.2020.12.001","article-title":"Early-onset developmental and epileptic encephalopathies of infancy: an overview of the genetic basis and clinical features","volume":"116","author":"Morrison-Levy","year":"2021","journal-title":"Pedia Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib29","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.seizure.2018.01.014","article-title":"Efficacy of lacosamide in children and adolescents with drug-resistant epilepsy and refractory status epilepticus: a systematic review","volume":"56","author":"Ortiz","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1684\/epd.2021.1244","article-title":"Developmental and epileptic encephalopathies: recognition and approaches to care","volume":"23","author":"Raga","year":"2021","journal-title":"Epileptic Disord."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib31","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1111\/epi.14071","article-title":"Long-term efficacy of add-on lacosamide treatment in children and adolescents with refractory epilepsies: a single-center observational study","volume":"59","author":"Rosati","year":"2018","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib32","doi-asserted-by":"crossref","unstructured":"Sanmarti-Vilaplana, F., and Diaz-Gomez, A. (2018). The effectiveness and safety of lacosamide in children with epilepsy in a clinical practice setting. doi: 10.1016\/j.yebeh.2017.11.024.","DOI":"10.1016\/j.yebeh.2017.11.024"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib33","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib34","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1055\/a-1942-2447","article-title":"Efficacy, retention rate, and influencing factors of ketogenic diet therapy in children with refractory epilepsy: a retrospective study","volume":"54","author":"Shen","year":"2023","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.pediatrneurol.2023.09.021","article-title":"Lacosamide for the treatment of seizures in neonates and infants: a retrospective assessment of efficacy and tolerability","volume":"149","author":"Shoaib","year":"2023","journal-title":"Pedia Neurol."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1093\/brain\/awaa371","article-title":"Developmental and epileptic encephalopathies: what we do and do not know","volume":"144","author":"Specchio","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib37","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40263-022-00898-1","article-title":"A practical guide to the treatment of dravet syndrome with anti-seizure medication","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1007\/s40263-022-00955-9","article-title":"Psychobehavioural and cognitive adverse events of anti-seizure medications for the treatment of developmental and epileptic encephalopathies","volume":"36","author":"Strzelczyk","year":"2022","journal-title":"CNS Drugs"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2021.108397","article-title":"Effectiveness of lacosamide in children and young adults previously treated with other sodium channel blockers","volume":"125","author":"Suzuki","year":"2021","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21176442","article-title":"Investigating developmental and epileptic encephalopathy using Drosophila melanogaster","volume":"21","author":"Takai","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib41","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1517\/14656566.2010.517194","article-title":"Pharmacotherapy for children and adolescents with epilepsy","volume":"12","author":"Verrotti","year":"2011","journal-title":"Expert Opin. Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib42","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1136\/jnnp-2020-323524","article-title":"Efficacy and safety of adjunctive lacosamide in the treatment of primary generalised tonic-clonic seizures: a double-blind, randomised, placebo-controlled trial","volume":"91","author":"Vossler","year":"2020","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109227","article-title":"Investigation of the efficacy and adverse effects of lacosamide over 36 months","volume":"144","author":"Wakabayashi","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib44","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12035-014-8775-9","article-title":"Specific binding of lacosamide to collapsin response mediator protein 2 (CRMP2) and direct impairment of its canonical function: implications for the therapeutic potential of lacosamide","volume":"51","author":"Wilson","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib45","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.seizure.2024.04.009","article-title":"Effectiveness and safety of lacosamide in pediatric patients with epilepsy under four years: results from a prospective cohort study in china","volume":"118","author":"Xiong","year":"2024","journal-title":"Seizure"},{"key":"10.1016\/j.eplepsyres.2025.107696_bib46","article-title":"Effectiveness and safety of lacosamide therapy for children with focal epilepsy: a real world study","volume":"14","author":"Yang","year":"2023","journal-title":"Front Pharm."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib47","doi-asserted-by":"crossref","DOI":"10.1111\/cns.14917","article-title":"Efficacy, safety, and tolerability of adjunctive lacosamide therapy for focal seizures in young children aged \u22651\u2009month to \u22644\u2009years: a real-world study","volume":"30","author":"Yang","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib48","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2023.109353","article-title":"Perampanel and lacosamide monotherapy in pediatric patients with newly diagnosed focal epilepsy: a prospective study evaluating efficacy, tolerability, and behavior","volume":"146","author":"Zhou","year":"2023","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2025.107696_bib49","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: position statement by the ILAE task force on nosology and definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001974?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121125001974?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,27]],"date-time":"2025-12-27T03:37:11Z","timestamp":1766806631000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121125001974"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":49,"alternative-id":["S0920121125001974"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107696","relation":{},"ISSN":["0920-1211"],"issn-type":[{"type":"print","value":"0920-1211"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The effectiveness and safety of lacosamide in infants with epilepsy aged under 2 years: A prospective study","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2025.107696","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"107696"}}